Driven by strong organic growth, an in-licensing agreement with Sanofi, the consolidation of Mantra, and the resolution of most legal challenges, Emcure is projected to achieve a 13% overall sales CAGR between FY2024 and FY2027. Enhanced productivity following a 20%+ expansion in field force since FY2022, along with increased utilisation of new facilities, is expected to contribute to robust EBITDA and EPS CAGRs of 18% and 29%, respectively, during the same period.
FPI buying returns to Dalal Street as global investors rethink AI bets
Foreign portfolio investors have shifted from aggressive selling to net buying of Indian equities recently. They invested nearly $1.2 billion over the last ten trading
November 2, 2026